The Company is a radiation oncology medical device company engaged in the development of its yttrium- 90 based brachytherapy device, RadioGelâ˘, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Companyâs development efforts. The Companyâs overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.
